By Dr Frances Theunissen and Dr Dev Nathani, Perron Institute
The rapidly evolving field of precision medicine and how it is reshaping the understanding and treatment of motor neurone disease (MND) was explored in a recent review led by WA researchers in collaboration with Kings College London.
Amyotrophic lateral sclerosis (ALS), the most common form of MND, is a life-limiting neurodegenerative disease, with the median survival being 2-4 years from disease onset.
Current available treatment options are limited with just two medications in Australia approved by the Therapeutics Goods Administration (TGA) and listed on the Pharmaceutical Benefits...
The rapidly evolving field of precision medicine and how it is reshaping the understanding and treatment of motor neurone disease (MND) was explored in a recent review led by WA researchers in collaboration with Kings College London.
Amyotrophic lateral sclerosis (ALS), the most common form of MND, is a life-limiting neurodegenerative disease, with the median survival being 2-4 years from disease onset.
Current available treatment options are limited with just two medications in Australia approved by the Therapeutics Goods Administration (TGA) and listed on the Pharmaceutical Benefits...
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.